Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia

The treatment of adults with ALL has undergone tremendous progress over the past 15 years. The advances have been particularly marked with B-lineage ALL. The development of bispecific antibodies directed against CD19 ushered in a new era in overcoming persistent minimal disease in newly diagnosed AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuasab, Tareq, Rowe, Jacob, Tvito, Ariella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536880/
https://www.ncbi.nlm.nih.gov/pubmed/34703207
http://dx.doi.org/10.2147/BTT.S290294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536880/
https://www.ncbi.nlm.nih.gov/pubmed/34703207
http://dx.doi.org/10.2147/BTT.S290294

Ejemplares similares